Literature DB >> 11429083

The crucial role of imaging in detection of facial nerve haemangiomas.

R J Salib1, E Tziambazis, A L McDermott, S V Chavda, R M Irving.   

Abstract

Facial nerve haemangioma is a rare benign neoplasm accounting for 0.7 per cent of all tumours involving the temporal bone. The diagnosis of a facial nerve tumour is often missed or delayed. Early diagnosis is imperative as it influences the eventual outcome for facial nerve function. Prognosis is related to the size of the tumour, the severity and the duration of pre-operative paralysis. The definitive diagnosis of a facial nerve tumour rests exclusively with high resolution imaging of the temporal bone using enhanced magnetic resonance imaging (MRI) and thin-sectioned computed tomography (CT). This case emphasizes the crucial role that high quality imaging can play in the diagnosis of facial nerve tumours, and elegantly illustrates the imaging features of facial nerve haemangiomas.

Entities:  

Mesh:

Year:  2001        PMID: 11429083     DOI: 10.1258/0022215011908090

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  4 in total

1.  Intralabyrinthine meningioma.

Authors:  Todd R Aho; C Phillip Daspit; Bruce L Dean; Robert C Wallace
Journal:  AJNR Am J Neuroradiol       Date:  2003-09       Impact factor: 3.825

Review 2.  The fallopian canal: a comprehensive review and proposal of a new classification.

Authors:  M M Mortazavi; B Latif; K Verma; N Adeeb; A Deep; C J Griessenauer; R S Tubbs; T Fukushima
Journal:  Childs Nerv Syst       Date:  2013-12-10       Impact factor: 1.475

Review 3.  Trigeminal neuralgia and facial nerve paralysis.

Authors:  Alexandra Borges
Journal:  Eur Radiol       Date:  2005-02-03       Impact factor: 7.034

4.  Resection of a Large Cavernous Hemangioma Following Preoperative Embolization in a Child's Temporal Bone.

Authors:  Yosaku Torii; Makoto Hosoya; Natsuki Hasebe; Shigeki Ogawa; Takenori Akiyama; Naoki Oishi; Kaoru Ogawa
Journal:  J Int Adv Otol       Date:  2021-05       Impact factor: 1.316

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.